Management of Elevated Liver Enzymes

Diagnostic Evaluation

The American Gastroenterological Association recommends a comprehensive diagnostic evaluation to identify the underlying cause of elevated liver enzymes, including a complete liver panel, viral hepatitis serologies, and autoimmune markers 1, 2
The European Association for the Study of the Liver suggests calculating the R-value to determine the injury pattern, with R ≥5 indicating hepatocellular injury and R ≤2 indicating cholestatic injury 1, 2
For women, a 4-fold elevation in ALT represents moderate elevation requiring systematic evaluation, according to the American College of Gastroenterology 3

The American Association for the Study of Liver Diseases recommends discontinuing suspected hepatotoxic medications immediately if drug-induced liver injury is suspected, and monitoring ALT every 3-7 days until a declining trend is established 1, 2, 3
For patients with non-alcoholic fatty liver disease (NAFLD), the American Gastroenterological Association suggests implementing lifestyle modifications, including a low-carbohydrate/low-fructose diet and 150-300 minutes of moderate-intensity aerobic exercise weekly 3
The European Association for the Study of the Liver recommends referring patients with suspected autoimmune hepatitis for liver biopsy confirmation 1, 3

The American College of Gastroenterology recommends monitoring liver enzymes every 2-4 weeks for patients with ALT 3-5× ULN, and every 4-8 weeks until normalized 3, 4
The American Association for the Study of Liver Diseases suggests urgent hepatology referral for patients with ALT >5× ULN, or those with evidence of synthetic dysfunction, such as prolonged PT/INR or low albumin 1, 2, 3

For patients on anti-tuberculosis therapy, the World Health Organization recommends monitoring ALT weekly for 2 weeks, then biweekly until normal, and stopping rifampicin, isoniazid, and pyrazinamide immediately if ALT ≥5× ULN or bilirubin rises 3
For patients on immune checkpoint inhibitors, the National Comprehensive Cancer Network recommends more frequent monitoring, every 1-2 weeks, due to the risk of immune-mediated hepatitis 3, 4